| Identification | Back Directory | [Name]
SJ-733 | [CAS]
1424799-20-1 | [Synonyms]
SJ-733
SJ-557733
(+)-SJ733
SJ000557733
(+)SJ733,(+)-SJ-733,(+) SJ733
(3S,4S)-N-(3-cyano-4-fluorophenyl)-1-oxo-3-(pyridi n-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroiso quinoline-4-carboxamide
4-Isoquinolinecarboxamide, N-(3-cyano-4-fluorophenyl)-1,2,3,4-tetrahydro-1-oxo-3-(3-pyridinyl)-2-(2,2,2-trifluoroethyl)-, (3S,4S)- | [Molecular Formula]
C24H16F4N4O2 | [MDL Number]
MFCD30532619 | [MOL File]
1424799-20-1.mol | [Molecular Weight]
468.4 |
| Chemical Properties | Back Directory | [Boiling point ]
633.1±55.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (106.75 mM) | [form ]
Solid | [pka]
11.91±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(+)-SJ733 is an anti-malaria agent which can also inhibit Na+-ATPase PfATP4. | [in vivo]
Treatment of P. falciparum-infected NOD-scid IL2Rγnull mice with (+)-SJ733 causes rapid clearance of parasites, which are 80% depleted within the first 24 h and undetectable by 48 h. (+)-SJ733 is highly potent and efficacious against P. falciparum 3D70087/N9in vivo when administered as four sequential daily oral doses in the NOD-scid IL2Rγnull mouse model, with a 90% effective dose, (ED90 1.9 mg/kg) and exposure [area under the curve at ED90 (AUCED90), 1.5 μM?h] superior to artesunate (11.1 mg/kg; AUCED90 not determined), chloroquine (4.3 mg/kg; AUCED90 3.1 μM?h), and pyrimethamine (0.9 mg/kg; AUCED90 5. μM?h) in the same model. When treated with the ED90 dose, (+)-SJ733 concentrations in blood remain above the average in vitro EC90 for 6 to 10 h after each dose[1]. | [IC 50]
Plasmodium | [References]
[1] Jimenez-Diaz MB, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. DOI:10.1073/pnas.1414221111 |
|
|